The seven-person startup develops technology to turn complex business documents into structured information that AI agents can use.
Isomorphic Labs raises $5 billion in Series C for AI drug discovery
The company aims to bring drug candidates into clinical trials and will use the funding to develop its technology and explore more types of medicine.

Isomorphic Labs has raised $5 billion in a Series C round led jointly by Greenoaks and Sequoia Capital, as the AI drug-discovery company seeks to advance drug candidates into clinical trials. The financing follows its $2.1 billion Series B in May.
Andreessen Horowitz participated as a new investor. All existing investors returned, including GV and Capital G, Alphabet’s venture divisions, as well as Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
The money will support further work on Isomorphic’s drug-design engine and expansion into more types of medicine. Its technology uses AI simulation models to investigate areas of chemistry and help design drugs.
Isomorphic emerged from Google’s DeepMind in 2021 and builds on its AlphaFold protein-folding model. The company said its program had delivered positive results in preclinical work in oncology and immunology. It has also reached agreements with Eli Lilly, Novartis and Johnson & Johnson.
The round marks the first fundraising since founder and CEO Demis Hassabis moved from leading DeepMind to a chairman role there to focus on drug discovery. Isomorphic disclosed no valuation for the financing. An earlier November media report said it was seeking funding at a valuation of $50 billion.
